Nuvectra (NASDAQ:NVTR) issued its quarterly earnings data on Wednesday. The company reported ($0.83) EPS for the quarter, missing the consensus estimate of ($0.65) by ($0.18), Bloomberg Earnings reports. Nuvectra had a negative net margin of 91.74% and a negative return on equity of 60.14%. The firm had revenue of $11.13 million for the quarter, compared to the consensus estimate of $12.76 million.
Shares of NASDAQ NVTR traded down $0.12 during midday trading on Friday, hitting $6.01. 3,108 shares of the company traded hands, compared to its average volume of 218,533. Nuvectra has a 12-month low of $5.91 and a 12-month high of $25.17. The company has a debt-to-equity ratio of 0.47, a current ratio of 5.81 and a quick ratio of 5.48. The stock has a market capitalization of $167.96 million, a P/E ratio of -1.88 and a beta of -0.18.
Several brokerages recently issued reports on NVTR. JMP Securities reduced their price target on shares of Nuvectra from $26.00 to $18.00 and set an “outperform” rating on the stock in a research report on Thursday. They noted that the move was a valuation call. ValuEngine cut shares of Nuvectra from a “hold” rating to a “sell” rating in a research report on Friday. BidaskClub upgraded shares of Nuvectra from a “sell” rating to a “hold” rating in a research report on Wednesday, February 20th. Finally, Raymond James reduced their price target on shares of Nuvectra from $23.00 to $18.00 and set an “outperform” rating on the stock in a research report on Friday, March 1st. Two research analysts have rated the stock with a sell rating and five have given a buy rating to the company’s stock. The stock presently has an average rating of “Hold” and an average price target of $20.40.
Nuvectra Company Profile
Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs.
Further Reading: Compound Interest and Why It Matters When Investing
Receive News & Ratings for Nuvectra Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nuvectra and related companies with MarketBeat.com's FREE daily email newsletter.